收藏切换
Cost-effectiveness analysis of recombinant human TNK tissue-type plasminogen activator in the treatment of acute ischemic stroke
收藏切换
Yu CHENa, Gang FANGa, Wei LIa, b, Jinxi DINGa, b, *
World Clinical Drug | 2026, 47(7) : 795 - 801
Less
收藏切换
World Clinical Drug | 2026, 47(7): 795-801
• Article •
Cost-effectiveness analysis of recombinant human TNK tissue-type plasminogen activator in the treatment of acute ischemic stroke
Full
Yu CHENa, Gang FANGa, Wei LIa, b, Jinxi DINGa, b, *
Affiliations
  • a.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • b.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2026-07-10 doi: 10.13683/j.wph.2026.07.014
Outline
收藏切换
Objective

To evaluate the cost-effectiveness of recombinant human TNK tissue-type plasminogen activator(TNK) versus alteplase in adult patients with acute ischemic stroke from the perspective of Chinese health system.

Methods

Based on individual patient data from the phase Ⅲ clinical trial TRACE-2(NCT04797013) of TNK in China, a decision tree and Markov hybrid model was constructed to simulate both a 1-year short-term and a lifetime horizon. The incremental cost-effectiveness ratio(ICER) of TNK versus alteplase was calculated, and sensitivity analysis were performed to test the robustness of the results.

Results

Compared with alteplase, TNK provided an incremental gain of 0.016 quality-adjusted life years(QALYs) and saved 65.29 yuan over a 1-year horizon, and provided 0.118 QALYs gained and saved 2 306.68 yuan over the lifetime horizon. TNK was dominant over alteplase in both time horizons.

Conclusion

From the perspective of the Chinese health system, TNK is cost-effective compared with alteplase for adult patients with acute ischemic stroke in China.

recombinant human TNK tissue-type plasminogen activator  /  acute ischemic stroke  /  pharmacoeconomics  /  cost-effectiveness analysis
陈渔, 方刚, 李伟, 丁锦希. 重组人TNK组织型纤溶酶原激活剂治疗急性缺血性脑卒中的成本-效果分析. 世界临床药物, 2026 , 47 (7) : 795 -801 . DOI: 10.13683/j.wph.2026.07.014
Yu CHEN, Gang FANG, Wei LI, Jinxi DING. Cost-effectiveness analysis of recombinant human TNK tissue-type plasminogen activator in the treatment of acute ischemic stroke[J]. World Clinical Drug, 2026 , 47 (7) : 795 -801 . DOI: 10.13683/j.wph.2026.07.014
Year 2026 volume 47 Issue 7
51
8
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.07.014
  • Receive Date:2025-10-30
  • Online Date:2026-11-05
  • Published:2026-07-10
Article Data
Affiliations
History
  • Received:2025-10-30
Affiliations
    a.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    b.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.07.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT